Guest Author I welcome as a co-author to this Perspective, Dr. Simon Ritchie, our lead investigator in skin disease and staff dermatologist, at San Antonio Military Health System, Fort Sam...
Read More
It has now been almost 18 months since I started my CEO Perspectives blog. From the questions and comments I get about my posts, I can tell that many people...
Read More
Galectin-3 is a protein, made predominantly in immune cells in the body, which binds to specific sugar molecules attached to many other types of proteins (called glycoproteins). By binding to...
Read More Results from the NASH-FX Study Underscore the Importance of Completing the NASH-CX Clinical Trial for Patients with NASH Cirrhosis
0 Comments , in Article
On September 27, 2016, we announced the results of our NASH-FX Phase 2a exploratory clinical study on the use of GR-MD-02 in nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis. While...
Read More
I often write about fatty liver disease, a problem that is gaining mainstream recognition as published earlier this year in Newsweek. It is easy to assume that this is a...
Read More
There was a big splash in the news recently about a study showing coffee drinking prevented cirrhosis. This seems to have struck a chord with people, and I’ve been getting...
Read More
Galectin Therapeutics is focused on a treatment for advanced fatty liver disease, or NASH (non-alcoholic steatohepatitis), which includes those patients with advanced scarring, or who are at the end stage...
Read More
We recently announced positive interim results from an open-label, Phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis (see press release here). On April 28th, I also...
Read More Pulmonary Arterial Hypertension is Associated with Elevated Levels of Galectin-3 and a Potential Therapeutic Target for GR-MD-02
1 Comments , in Article
Elevated levels of the Galectin-3 protein are associated with multiple disease processes, in addition to those Galectin Therapeutics is addressing in ongoing clinical trials such as fatty liver disease, psoriasis...
Read More
By Peter G. Traber, M.D. on April 28, 2016 Last September, Galectin Therapeutics began a Phase 2a open-label clinical trial with GR-MD-02, our galectin-3 inhibitor drug, in patients with moderate-to-severe...
Read More